C-HV3HTAmiRNA
RNA biomarkers, microRNA diagnostics, extracellular vesicles
modulatingrna therapeutic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-HV3H
C-HV3HC-HV3HRNA biomarkers, microRNA diagnostics, extracellular vesicles
0-100 chain-logic scale · 15 dimensions · scored on public evidence
TAmiRNA RNA biomarkers, microRNA diagnostics, extracellular vesicles
TAmiRNA supports researchers and clinicians in RNA biomarker discovery, validation, and development. The company specializes in cell-free RNAs, including microRNAs, mRNAs, and long non-coding RNAs, and integrates RNA signatures with AI-driven analysis. Its R&D and contract research focus includes liver disease, senescence, cardiovascular disease, oncology, and bone and joint disorders.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
TAmiRNA — Early mechanism · Lower middle. Derived deterministically from 6 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (4 programs at preclinical).…
Source: Deterministic